Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05842434 · ClinicalTrials.gov registry record · NA
Pilot Study of the Felix System in Patients With Essential Tremor and Parkinson's Tremor
A NA study, sponsored by Fasikl.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT05842434: Completed NA study, sponsored by Fasikl.
NCT05842434 is a NA study that has completed, run by Fasikl. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05842434, a NA study, has completed, sponsored by Fasikl.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
A prospective, open-label, multi-center pilot study designed to evaluate the safety and effectiveness of the Felix system in the relief of upper limb tremors in adults with essential tremor and Parkinson's disease.
Primary Outcome
A subset of 6 performance tasks will be rated by a physician for each upper limb separately. Each task will be rated from 0 to 4, indicating the increasing severity of tremor, the higher the score, the worse the tremor. This endpoint is the total score of all 6 tasks, the minimum score is 0 and the maximum score is 24.
Interventions
- DEVICE Felix NeuroAI Wristband
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2023-06-06 |
| Est. Completion | 2023-11-29 |
| Phase | NA |
What the finished NCT05842434 record still lists
NCT05842434 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Felix NeuroAI Wristband is the first listed.
NCT05842434 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05842434 about?
NCT05842434 is a clinical study titled "Pilot Study of the Felix System in Patients With Essential Tremor and Parkinson's Tremor". A prospective, open-label, multi-center pilot study designed to evaluate the safety and effectiveness of the Felix system in the relief of upper limb tremors in adults with essential tremor and Parkinson's disease.
What is the current status of trial NCT05842434?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2023-06-06. Estimated completion is 2023-11-29.
What interventions are being tested in trial NCT05842434?
The interventions under investigation include: Felix NeuroAI Wristband (DEVICE).
Who is sponsoring clinical trial NCT05842434?
This trial is sponsored by Fasikl, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05842434's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI